Targeting GPX4 to Induce Ferroptosis Overcomes Chemoresistance Mediated by the PAX8‐AS1 /GPX4 Axis in Intrahepatic Cholangiocarcinoma
Advanced Science · 2025-08 · 12 (30)
DOI: 10.1002/advs.202501042 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 20.05.2025. Verfasst von Zhi-Wen Chen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatic Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, 200032, China. Hauptthemen laut MEDLINE: Ferroptosis, Cholangiocarcinoma, Drug Resistance, Neoplasm, Phospholipid Hydroperoxide Glutathione Peroxidase. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Anti-cancer Association's Aoxiang Project, Key Project of Xuhui District Municipal Health Commission, Shanghai Xuhui District Hospital Local Cooperation Project.
Abstract (Originalsprache)
The standard regimen of gemcitabine combined with cisplatin offers limited clinical benefits in the treatment of advanced intrahepatic cholangiocarcinoma (ICC) due to intrinsic or acquired resistance. Currently, effective biomarkers to predict and improve chemotherapy resistance in ICC are lacking. Here, it is reported that a long non‐coding RNA (lncRNA), PAX8‐AS1 , reduces the efficacy of standard chemotherapeutic drugs. Mechanistically, PAX8‐AS1 activates NRF2 by binding to p62, thereby promoting GPX4 transcription, and stabilizes GPX4 mRNA through interaction with IGF2BP3. The PAX8‐AS1 /GPX4 axis inhibits ferroptosis and promotes resistance to gemcitabine and cisplatin. In preclinical models, the combination of the GPX4 inhibitor JKE‐1674 with gemcitabine and cisplatin exhibits superior antitumor efficacy. These findings suggest a promising therapeutic strategy to improve chemotherapy efficacy in advanced ICC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatic Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
ORCID-Profile: Zhi-Wen Chen, Lu Wang
Förderung
- Shanghai Anti-cancer Association's Aoxiang Project
- Key Project of Xuhui District Municipal Health Commission
- Shanghai Xuhui District Hospital Local Cooperation Project
- Beijing iGandan Foundation
- Chen Xiao-Ping Foundation for the Development of Science and Technology of Hubei Province
- National Natural Science Foundation of China
Zitieren
APA
Chen, Z. W., Shan, J. J., Chen, M., Wu, Z., Zhao, Y. M., Zhu, H. X., Jin, X., Wang, Y. X., Wu, Y. B., Xiang, Z., Ding, Z. W., Lin, Z. H., Wang, L. R., & Wang, L. (2025). Targeting GPX4 to Induce Ferroptosis Overcomes Chemoresistance Mediated by the PAX8‐AS1 /GPX4 Axis in Intrahepatic Cholangiocarcinoma. Advanced Science, 12(30). https://doi.org/10.1002/advs.202501042
Vancouver
Chen ZW, Shan JJ, Chen M, Wu Z, Zhao YM, Zhu HX, et al. Targeting GPX4 to Induce Ferroptosis Overcomes Chemoresistance Mediated by the PAX8‐AS1 /GPX4 Axis in Intrahepatic Cholangiocarcinoma. Advanced Science. 2025;12(30). doi:10.1002/advs.202501042
BibTeX
@article{Chen2025,
author = {Chen, Zhi-Wen and Shan, Ji-Jun and Chen, Mo and Wu, Zong and Zhao, Yi-Ming and Zhu, Hong-Xu and Jin, Xin and Wang, Yi-Xiu and Wu, Yi-Bin and Xiang, Zhen and Ding, Zhi-Wen and Lin, Zhen-Hai and Wang, Long-Rong and Wang, Lu},
title = {Targeting GPX4 to Induce Ferroptosis Overcomes Chemoresistance Mediated by the PAX8‐AS1 /GPX4 Axis in Intrahepatic Cholangiocarcinoma},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {30},
doi = {10.1002/advs.202501042}
}
EUVIMED